The present invention has for object the use of minocycline or its equivalent forms, or of any form of tetracycline in combination with Fluconazole or any of its equivalent form with antifungal capacity and atorvastatin or any equivalent form (lipophilic statins) for the preparation of a single compound directed to the treatment of every type of multiple sclerosis or diseases etiopathologically equivalents, whether it be of remitting relapsing or progressive, but anyway degenerative kind, considering the weaker of subject that will receive it as consequence of previous treatments or state of illness. The effectiveness of this combination has been shown from many researches on single components. To date, given the proven efficacy of the individual components, the low toxicity of the same and the long period of the marketing thereof, as well as the observed greater efficiency of the combination of the same used in accordance with the overexposed new mode of use, it can be said that the above-mentioned new compound derived from a combination of minocycline or its equivalent forms, or of any form of tetracycline in combination with Fluconazole or any of its equivalent form with antifungal capacity and atorvastatin or any equivalent form (lipophilic statins), is effective in reduce the incidence of the disease on quality of life of the patient with the designed dosage that never has been determined before.
